RxDoctor Payments Data

Rafael Sanchez Ponce, MD

Interventional Cardiology · Trinity, FLNPI 1669433223

Payments from drug & device makers

$16,816in general payments, 2019–2025

Across 497 payments — averaging $33.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • AstraZeneca$2K
  • Boston Scientific$1K
  • Johnson & Johnson$1K
  • Abbott$1K
  • Abiomed$1K
  • plus $7K from 33 others

What the payments were for

  • Travel & lodging$1,1917%
  • Food & beverage$15,44392%
  • Education$1821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,816 in reported general payments places this provider in the 60th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$193,116
Medicare patients
656
Services billed
1,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$128,978
XareltoRivaroxaban64$81,184
EntrestoSacubitril/Valsartan64$68,936
FarxigaDapagliflozin Propanediol45$49,500
BrilintaTicagrelor23$15,497
Metoprolol Succinate303$4,362
Ranolazine ErRanolazine44$2,801
Amiodarone Hcl58$1,897
Isosorbide Mononitrate ErIsosorbide Mononitrate153$1,784
ClopidogrelClopidogrel Bisulfate149$1,659
Losartan Potassium165$1,390
Cilostazol26$931
Bumetanide43$923
Doxazosin Mesylate42$877
Amlodipine Besylate186$876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$305$128,978134 claims
Johnson & JohnsonXarelto$1,439$81,18464 claims
NovartisEntresto$694$68,93664 claims
AstraZenecaFarxiga, Brilinta$2,283$64,99668 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Trinity

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →